REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
==== Metabolism ==== In terms of metabolism, methenamine is hydrolyzed to form formaldehyde and ammonium in acidic urine (pH < 6). More specifically, a single molecule of methenamine decomposes into six equivalents of formaldehyde and four ammonia molecules. The drug may be degraded 10 to 30% in the acidic environment of the stomach prior to absorption. This can be avoided with enteric coated tablets. In terms of pH, there is minimal hydrolysis at a pH of 7.4, 6% at a pH of 6, and 20% at a pH of 5. The hydrolysis of methenamine occurs slowly and gradually, with approximately 3 hours required for 90% decomposition into formaldehyde. As breakdown of methenamine only occurs in acidic environments like the bladder and stomach, the activation of methenamine into formaldehyde in the body is tissue-selective. Following its formation, formaldehyde is rapidly metabolized into formic acid (formate) in the body.
The authentic idea of the unity of the Slavic people was all but gone after World War I, described with the maxim "Versailles and Trianon have put an end to all Slavisms". During the Cold War, all Slavic peoples were in union under the dominance of the USSR, but pan-Slavism was rejected as reactionary to Communist ideals, and this unity was largely put to rest with the fall of communism in Central and Eastern Europe in the late 1980s, leading to the breakup of federal states such as Czechoslovakia and Yugoslavia. Varying relations between the Slavic countries exist nowadays; they range from mutual respect on equal footing and sympathy towards one another through traditional dislike and enmity, to indifference. No forms, other than culture and heritage oriented organizations, are currently considered forms of rapprochement among the countries with Slavic origins. The political parties which include Pan-Slavism as part of their program usually live on the fringe of the political spectrum, or are part of controlled and systemic opposition in Belarus, Russia and occupied territories, as part of an irredentist pan-slavist campaign by Russia. A political concept of Euro-Slavism evolved from the idea that European integration will solve issues of Slavic peoples and promote peace, unity and cooperation on equal terms within the European Union. The concept seeks to resist strong multicultural tendencies from Western Europe, the dominant position of Germany, opposes Slavophilia, and typically encourages democracy and democratic values.
== Treatment == Myxomas are usually removed surgically. The surgeon removes the myxoma, along with at least 5 surrounding millimeters of atrial septum. The septum is then repaired, using material from the pericardium.
Amazon services include its digital assistant Alexa, Amazon Music, and Prime Video for music and videos respectively, the Amazon Appstore for Android apps. Audible provides audiobooks for purchase and listening. RXPass is a US prescription drug delivery service. US Amazon Prime members can pay a $5 monthly fee for access to 60 medications. Beneficiaries of government healthcare programs such as Medicare and Medicaid are not eligible. Amazon Live is an e-commerce live-streaming service. The service allows promoters to stream live videos promoting or sponsoring products. Promoters (mainly celebrities or Internet influencers) can add tags to add context. Other users can watch and send messages to a global chat for any stream. In 2023 roughly a billion total viewers watched streams in the US and India. The platform is integrated into Amazon Freevee and Amazon Prime Video.
Sources: en.wikipedia.org
=== Marketing authorization === In 2011, the European Medicines Agency (EMA) granted a marketing authorisation for a buccal application form of midazolam, sold under the brand name Buccolam. Buccolam was initially approved for the treatment of prolonged, acute, convulsive seizures in people from three months to less than 18 years of age. This is the first application of a paediatric-use marketing authorisation by the EMA.
== Awards == Silver medal, 2022 International KIWIE Award Silver medal, 2023 International KIWIE Award. Women Inventor Award, INDECOPI. Top 10 iCAN Award, from Canada for her ongoing projects. Hipolito Unanue Institute Fountation Award, Best Scientific Research Work for the study "Frequency of CYP1A1*2A and deletion of the GSTM1 gene in the Peruvian mestizo population". Three gold medals, 2024 International KIWIE Awards
=== Beginnings and FA Cup glory === Barnsley were established in 1887 as Barnsley St Peter's by Reverend Tiverton Preedy, and they played in the Sheffield and District League from 1890 and in the Midland League from 1895. In 1897, the club dropped the St Peter's part of its name to become simply Barnsley. They joined the Football League in 1898, and struggled in the Second Division for the first decade, due in part to ongoing financial difficulties. In 1910, the club reached the FA Cup final, where they were defeated by Newcastle United. In 1912, they reached the FA Cup final again, and defeated West Bromwich Albion 1–0 to win the trophy for the first time in their history. When league football restarted after the First World War, the 1919–20 season brought some significant changes to the league. The main difference was that the First Division would now have 22 teams, rather than 20. The bottom team from the previous season was Tottenham Hotspur and they were relegated. The first extra place in the First Division went to Chelsea, who retained their place despite finishing second bottom and therefore in the relegation places. Derby County and Preston North End were promoted from the Second Division which left one place to be filled. Having finished the previous season's Second Division in third place, Barnsley expected to achieve First Division status for the first time, but the Football League instead chose to call a ballot of the clubs. The League voted to promote sixth-placed Arsenal, prioritizing historical standing over sporting merit.
In 2017, the U.S. Food and Drug Administration (FDA) approved L-glutamine oral powder, marketed as Endari, to reduce severe complications of sickle cell disease in people aged five years and older with the disorder. The safety and efficacy of L-glutamine oral powder were studied in a randomized trial of subjects ages five to 58 years old with sickle cell disease who had two or more painful crises within the 12 months prior to enrollment in the trial. Subjects were assigned randomly to treatment with L-glutamine oral powder or placebo, and the effect of treatment was evaluated over 48 weeks. Subjects who were treated with L-glutamine oral powder experienced fewer hospital visits for pain treated with a parenterally administered narcotic or ketorolac (sickle cell crises), on average, compared to subjects who received a placebo (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital (median 6.5 days vs. median 11 days). Subjects who received L-glutamine oral powder also had fewer occurrences of acute chest syndrome (a life-threatening complication of sickle cell disease) compared with patients who received a placebo (8.6 percent vs. 23.1 percent). Common side effects of L-glutamine oral powder include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. L-glutamine oral powder received orphan drug designation. The FDA granted the approval of Endari to Emmaus Medical Inc.
=== Media === Castillo has been accused of being evasive with the press. He has not offered any interviews to inform of projects or ideas, and the Council of Ministers has suspended press conferences. Members of Castillo's cabinet have expressed reluctance of communicating with the press, due to the belief that the media maliciously distorts information. According to a poll from 17 August 2021, 78% of respondents believe that the president maintains an inadequate relationship with the press, while only 15% of respondents consider the president's relationship to be adequate. On 20 September 2021, the Free Peru caucus proposed a bill which would declare the "public necessity and national interest the fair and equitable distribution of the electromagnetic and radioelectric spectrum in radio, television and other media." This would allow the government to take direct control of the media given an "exceptional and transitory nature." The bill was signed by 7 members of Free Peru, out of the 37 Congressmen it wields. Some newspapers have claimed that those who gave their signature to the bill are close to Vladimir Cerrón. The opposition has criticized the broad and vague nature of this proposed media bill, which could be applied to the internet and any information platform. Castillo's Foreign Minister, Óscar Maúrtua also condemned the proposed bill, saying that it would "certainly affects international commitments...
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.